Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Nerve Growth Factor Delivery into the Brain – focus on therapeutic potential in Alzheimer’s disease and In Vivo Evaluation via PET

Beyond the BBB

Alzheimers disease (AD) is a neurodegenerative disease affecting the aged population and is projected to increase 3-fold in the next 30 years. Treatment options in AD are limited due to complex pathological processes and the blood-brain barrier (BBB), which restrict entry molecules into the brain. A finding in AD is the loss of cholinergic neurons...

Funding Programme
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved

Network-based prediction of spreading of tau pathology in Alzheimer’s disease: implications for clinical trials

networkAD

Alzheimer’s disease (AD) has far-reaching societal and economic consequences, emphasizing the urgent need for effective treatment solutions. However, to date, over 99% of AD clinical trials have failed. Inadequate patient stratification is a key contributing factor due to the enormous clinical and pathological heterogeneity in AD. AD is...

Funding Programme
Start Date
End Date
Total Funding
€ 222 727
European Countries Involved

Neural correlates of narrative discourse in mild cognitive impairment

NEUROCOG

The goal of the proposal is to identify the association of different narrative perseverations features in mild cognitive impairment (MCI) subtypes with their neural oscillatory profiles. MCI patients show moderately impaired performance on neuropsychological tests but relatively intact global cognition and daily functioning. Validated as different...

Funding Programme
Start Date
End Date
Total Funding
€ 265 099
European Countries Involved

Neuronal networks dynamics underlying spike timing precision during brain developmental plasticity and Alzheimer's disease progression.

STDP-development-AD

Brain plasticity and neuronal network oscillations are crucial brain processes that depend on the timing precision of neuronal activity. These processes change during healthy brain development and are disrupted early on Alzheimers disease (AD) with controversies on the onset of their impairment. Thus, comprehensive studies of plasticity considering...

Funding Programme
Start Date
End Date
Total Funding
€ 193 402
European Countries Involved

Neuroprosthetic Modulation of Large-Scale Brain Networks for Treating Memory Disorders

MEMOPROSTHETICS

Cognitive deficits caused by ageing, neurodegenerative diseases or brain injury represent a major public health issue. They are associated with a disruption of neural oscillations in large-scale brain networks, which cannot be restored using current treatments. Here, I propose a new neuromodulation framework for manipulating neural oscillations...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 625
European Countries Involved

Neuropsychiatric Impairments and Neurotransmitter-related Functional Alterations in Alzheimer’s Disease

NINFA-AD

Depressed mood, agitation, false beliefs, lack of motivation and other alterations in behaviour, usually named with the umbrella term of neuropsychiatric symptoms (NPS), are commonly observed in people with Alzheimers disease (AD). NPS are highly prevalent in people with AD (35-85%) and increase the risk of dementia by up to 10 times. The onset of...

Funding Programme
Start Date
End Date
Total Funding
€ 172 750
European Countries Involved

NeurovasculAR coupling and Neuronal Infraslow Activity

NARNIA

Cerebral autoregulation and neurovascular coupling have a critical role in sustaining brain activity and preventing irreversible damage. Yet, despite revolutionary advances in neuroimaging methods questions remain on the relation and reciprocal interactions between cerebral hemodynamics (blood flow, oxygenation, vascular regulation) and neuronal...

Funding Programme
Start Date
End Date
Total Funding
€ 181 152
European Countries Involved

Neutrophil Extracellular Traps Induced Glial Type I Interferon in the Pathogenesis of Tauopathy

TNT

Tauopathies, including Alzheimer’s Disease (AD), characterized by the brain accumulation of abnormal Tau proteins, represent a significant unmet medical need. Neuroinflammation is a hallmark of these diseases. Although several neuroimmune regulations, notably involving microglia, have been largely studied recently, the role of neutrophils and the...

Funding Programme
Start Date
End Date
Total Funding
€ 242 260
European Countries Involved

Non-Animal Platform for Nanoparticle-Based Delivery across the blood-brain barrier Interface with Vehicle Evolution

NAP4DIVE

The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson's, Alzheimer's, Schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and...

Funding Programme
Start Date
End Date
Total Funding
€ 7 767 276
European Countries Involved

Non-invasive detection of interictal epileptiform discharges (IEDs) in the mesial temporal lobe (MTL) during sleep

InterictalSleepDetct

Interictal epileptic discharges (IEDs) are pathological brain activities involving sharp spikes in electrical field potentials that occur preferentially during sleep. In epilepsy, IEDs occur between seizures, and often in deep brain regions such as the medial temporal lobe (MTL).IEDs during sleep disrupt memory and are associated with cognitive...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease

ADVANCE-AD

Alzheimers disease (AD) is the most common cause of dementia and a major global health challenge. AD has a long pre-symptomatic phase spanning several decades. The accuracy of clinical AD diagnostics is mediocre, especially in primary care. This results in suboptimal treatment and care, which is especially problematic in light of emerging anti...

Funding Programme
Start Date
End Date
Total Funding
€ 2 500 000
European Countries Involved

Novel Integrated Approach for Assembly Analysis of Intrinsically Disordered Proteins at High Resolution

IDP Assembly

Protein aggregation hallmarks several neurodegenerative diseases, including Alzheimer's and Parkinson's. In Parkinson's, aggregation of the intrinsically disordered protein (IDP) alpha-synuclein (Syn) leads to its intracellular deposition into Lewy bodies, which causes neuronal dysfunction. Recently it was discovered that Syn can undergo liquid...

Funding Programme
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).